Bayer’s Stivarga First Drug To Enter Brain Cancer Platform Trial
GBM AGILE is the first global adaptive clinical trial platform for glioblastoma and the German group's liver and colorectal cancer drug will be the first of several therapies to be studied.
You may also be interested in...
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.